What is DAWN stock price today?

DAWN (Day One Biopharmaceuticals Inc) stock is trading at $12.11 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is DAWN stock going up or down today?

DAWN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy DAWN stock now?

The decision to buy DAWN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is DAWN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for DAWN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is DAWN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if DAWN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is DAWN's P/E ratio?

P/E ratio data for DAWN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is DAWN's market cap?

DAWN (Day One Biopharmaceuticals Inc) has a market capitalization of $1.04 billion, making it a small-cap stock.

What is DAWN's price to book ratio?

DAWN trades at a price-to-book (P/B) ratio of 2.31, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does DAWN pay dividends?

DAWN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is DAWN's dividend yield?

DAWN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is DAWN stock a good long-term investment?

DAWN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is DAWN's revenue growth rate?

DAWN has shown revenue growth of -0.6% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

DAWN is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in DAWN?

Key risks for DAWN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does DAWN compare to its competitors?

Compare DAWN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize DAWN's performance and positioning.

What is DAWN's stock price target for 2026?

Our AI model provides price targets for DAWN based on fundamental analysis: Bull case $15.74 (+30%), Base case $13.93 (+15%), Bear case $10.90 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about DAWN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for DAWN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is DAWN's next earnings report?

DAWN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

DAWN - Day One Biopharmaceuticals Inc

NYSE * Health Care * Biotechnology

$12.11

+$1.95 (+19.19%)

About Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

DAWN Key Statistics

Market Cap

$1.04B

P/B Ratio

2.31

EPS

$-1.52

Revenue Growth

-0.6%

Profit Margin

-1.1%

Employees

181

How DAWN Compares to Peers

DAWN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
DAWN(This stock)	$1.04B	N/A	-1%	-1.1%	-
AMGNAmgen Inc	$177.92B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.99B	19.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.16B	31.1	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.69B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Day One Biopharmaceuticals Inc Company Information

Headquarters: California; U.S.A
Website: www.dayonebio.com
Sector: Health Care
Industry: Biotechnology

DAWN - Day One Biopharmaceuticals Inc

About Day One Biopharmaceuticals Inc

DAWN Key Statistics

How DAWN Compares to Peers

Day One Biopharmaceuticals Inc Company Information

DAWN Lician Score

DAWN Financial Snowflake

Upcoming Events for DAWN